Nipro North America, a division of Nipro Medical Corporation, announced the launch of the Cronus HP high-pressure, 0.035″ over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter.
Background
Nipro says Cronus HP is is the latest product offering from its Interventional Division. It is a 0.035″ guidewire-based balloon percutaneous transluminal angioplasty(PTA) system available in a wide range of lengths and diameters to treat focal, as well as diffuse AVF stenoses. The device is indicated for PTA in the femoral, popliteal, iliac and renal arteries and for the treatment of obstructive lesions in native or synthetic arteriovenous dialysis fistulae.
The combination of high pressure, flexibility and durability allow Nipro to deliver a product that addresses the limitations of conventional high pressure PTA balloons. Cronus HP claims an average rated burst pressure of 26 atmospheres across the entire size matrix. This semi-compliant balloon provides unparalleled flexibility at high pressure, while minimizing balloon elongation and “dog bone” effect. The device is intended to treat AVF stenoses ranging from simple, focal, venous outflow strictures to more complex juxta-anastomotic obstructions in early fistula failures.
Company comments
“Cronus HP provides physicians with a high-pressure PTA balloon catheter, specifically designed to successfully balloon the most resilient stenoses that are typically resistant to expansion, while being flexible enough to conform to natural vasculature of native fistulae. This is particularly important at and across the anastomosis, where less vessel straightening leads to minimal vascular damage and superior outcomes,” said John O’Connor, National Sales Manager for Nipro’s Interventional Division.
Joe Dawson, Senior Vice President for Nipro North America stated; “Optimal blood flow dynamics are critical for maintaining treatment adequacy in patients with native AV fistulae of synthetic AV grafts. Nipro is committed to manufacturing products that give physicians the added tools necessary for procedural success and lower treatment times, minimizing post-procedural complications and bringing overall superior outcomes.”
Source: PR Newswire
published: February 19, 2016 in: Launches / Withdrawals, Vascular